Company / Return on Equity (ROE)
NewAmsterdam Pharma Co N.V. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-29.8%
FY2025
5-year range
-61.4% / -5.3%
FY2022-FY2025
Trend
+6.5%
vs FY2024
Sector context
#101 of 190
Health Care
What the data says
NewAmsterdam Pharma Co N.V. reports negative total equity of -29.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-29.8% in FY2025 with a 3-year CAGR of -24.6%.
Improved from -61.4% to -29.8% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -24.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#101 of 190 in Health CareTop 53% of 190This company -29.8% Sector average -29.0%
▼
-3.0% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 6.5% year-over-year.
- Currently 0.9pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -29.8% | +6.5% |
| FY2024 | -31.9% | +48.0% |
| FY2023 | -61.4% | -1066.3% |
| FY2022 | -5.3% | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026